Stemline Therapeutics, Inc. (STML)

Home » Stocks » STML

Jun 10, 2020 - STML was delisted (reason: company went private)

Stock Price: $11.83 USD 0.00 (0.00%)

Updated Jun 10, 2020 4:00 PM EDT

• Overview
• News
• Financials

Key Info

Market Cap	621.13M
Revenue (ttm)	47.04M
Net Income (ttm)	-70.70M
Shares Out	52.50M
EPS (ttm)	-1.58
PE Ratio	n/a
Forward PE	17.92
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	Jun 10, 2020
Last Price	$11.83
Previous Close	$11.83
Change ($)	0.00
Change (%)	0.00%
Day's Open	-
Day's Range	11.82 - 12.10
Day's Volume	0
52-Week Range	3.21 - 18.22

More Stats

Market Cap	621.13M
Enterprise Value	470.72M
Earnings Date (est)	Jul 31, 2020
Ex-Dividend Date	n/a
Shares Outstanding	52.50M
Float	n/a
EPS (basic)	-1.58
EPS (diluted)	-1.58
FCF / Share	-1.24

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	3.28M
Short Ratio	1.13
Short % of Float	n/a
Beta	1.74

PE Ratio	n/a
Forward PE	17.92
P/FCF Ratio	n/a
PS Ratio	13.20
PB Ratio	4.21
Revenue	47.04M
Operating Income	-73.16M
Net Income	-70.70M
Free Cash Flow	-59.33M

Net Cash	150.41M
Net Cash / Share	2.86
Gross Margin	-26.36%
Operating Margin	-155.52%
Profit Margin	-150.30%
FCF Margin	-126.12%
ROA	-29.81%
ROE	-55.12%
ROIC	-55.70%

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy	1
Overweight	0
Hold	4
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: Overweight

Price Target

$12.50*

(5.66% upside)

Low

12.5

Current: $11.83

High

12.5

Target: 12.50

*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Income Statement | Balance Sheet | Cash Flow

Year	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	43.22	0.50	0.90	1.04	0.65	0.34	0.07	-	-	-
Revenue Growth	8543.37%	-44.33%	-13.75%	59.19%	95.1%	372.24%	-	-	-	-
Gross Profit	38.32	0.50	0.90	1.04	0.65	0.34	0.07	-	-	-
Operating Income	-79.25	-86.29	-68.56	-38.89	-37.63	-28.99	-23.98	-6.47	-2.73	-2.26
Net Income	-76.82	-85.02	-67.83	-38.30	-37.24	-28.83	-24.20	-6.27	-2.75	-1.80
Shares Outstanding	42.09	28.39	23.06	17.80	17.29	12.94	10.32	3.44	3.44	3.30
Earnings Per Share	-1.83	-2.99	-2.94	-2.15	-2.15	-2.23	-2.35	-1.82	-0.80	2.81
Operating Cash Flow	-67.69	-72.18	-49.62	-30.09	-25.59	-25.71	-16.12	-4.13	-1.94	-1.86
Capital Expenditures	-0.06	-0.11	-0.13	-0.01	-0.02	-	-0.46	-	-	-
Free Cash Flow	-67.75	-72.29	-49.75	-30.10	-25.61	-25.71	-16.58	-4.13	-1.94	-1.86
Cash & Equivalents	164	60.11	51.72	46.88	46.04	53.98	44.20	2.03	5.83	-
Total Debt	1.40	-	-	-	-	-	-	2.01	1.57	-
Net Cash / Debt	163	60.11	51.72	46.88	46.04	53.98	44.20	0.02	4.26	-
Assets	187	63.49	67.01	68.12	98.22	60.49	85.28	5.03	6.45	-
Liabilities	23.36	21.29	19.94	10.40	10.10	5.08	5.66	7.54	3.25	-
Book Value	164	42.20	47.07	57.72	88.11	55.41	79.62	-2.51	3.21	-

Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name	Stemline Therapeutics, Inc.
Country	United States
Employees	100
CEO	Ivan Bergstein

Stock Information

Ticker Symbol	STML
Stock Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NASDAQ: STML
IPO Date	January 29, 2013

Description

Stemline Therapeutics, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is headquartered in New York, New York.